Sign Out
Pregnancy: Lacosamide crosses the placenta. Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of lacosamide may be altered. Information related to pregnancy outcomes following maternal use of lacosamide is limited. In general, maternal polytherapy with antiepileptic drugs may increase the risk of congenital malformations, monotherapy with the lowest effective dose is recommended. Newborns of women taking antiepileptic medications may be at an increased risk of adverse events.
Breastfeeding: Lacosamide is present in breast milk. Drowsiness and poor feeding were observed in a breastfeeding newborn following maternal use of lacosamide (in combination with other medications) throughout pregnancy and postpartum. The decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.
Continue with Google